David House was named Chief Financial Officer of Armata Pharmaceuticals, Inc., effective July 17, 2026. As of November 6, 2026, Armata Pharmaceuticals, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 27, 2026 to July 20, 2026, naming 2 appointments (Form 8-K, July 20, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Armata Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: David House · Role: Chief Financial Officer · Effective: 2026-07-17 · 8-K, 2026-07-20
- · In / out: Reported · Person: not named in the filing · 8-K/A, 2026-06-24
- · In / out: In · Person: Daniel Gilmer · Role: Director · Effective: 2026-04-24 · 8-K, 2026-04-27
Armata Pharmaceuticals, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-27 to 2026-07-20. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Armata Pharmaceuticals, Inc. files it.
Also on the record for Armata Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 13, 2026 | Stake report, Schedule 13D/A, by Innoviva, Inc. | 82.7% of the class | 5%+ stakes | Source |
| January 26, 2026 | Stake report, Schedule 13D/A, by Innoviva, Inc. | 83.1% of the class | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13D/A, by Innoviva, Inc. | 83.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Armata Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Armata Pharmaceuticals, Inc. and the records around it.
Armata Pharmaceuticals, Inc. elsewhere on the record
Watch Armata Pharmaceuticals, Inc.
Get an email when Armata Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Armata Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Armata Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Armata Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-20 | In | Chief Financial Officer | 2026-07-17 | 8-K, 2026-07-20 | |
| 2026-06-24 | Reported | not named in the filing | 8-K/A, 2026-06-24 | ||
| 2026-04-27 | In | Director | 2026-04-24 | 8-K, 2026-04-27 |
Who leads Armata Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: David House, appointed, effective 2026-07-17 (filed 2026-07-20).
- Director: Daniel Gilmer, appointed, effective 2026-04-24 (filed 2026-04-27).
New leaders reset buying decisions — get the Full Report on Armata Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Armata Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Armata Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: David House, Chief Financial Officer, effective 2026-07-17
On July 17, 2026, the Board of Directors (the " Board ") of Armata Pharmaceuticals, Inc. (the " Company ") promoted and appointed David House as the Company's Chief Financial Officer, effective July 17, 2026.
- Mr. House previously served as the Company's Senior Vice President, Finance and principal financial officer since August 2024.
- In connection with Mr. House's appointment as Chief Financial Officer, the Company and Mr. House entered into an employment letter agreement, dated July 17, 2026 (the "House Agreement"), which confirms the terms of Mr. House's continued employment with the Company from and after the date thereof.
- Pursuant to the House Agreement, Mr. House will serve as the Company's Chief Financial Officer, reporting directly to the Company's Chief Executive Officer.
- Pursuant to the House Agreement, Mr. House will receive an annual base salary of $371,315, and will be eligible for a target annual bonus opportunity equal to 50% of his base salary, with the actual bonus payable based on actual performance as determined by the Board or compensation committee.
- Mr. House's annual target performance bonus percentage is subject to increase, but not decrease, from time to time in the discretion of the Board or the compensation committee.
- The House Agreement provides that Mr. House will be eligible to receive annual equity awards pursuant to the Company's 2016 Equity Incentive Plan or any successor plan commencing in 2026.
Reported
Such cash retainer will be pro-rated based on the effective date of Dr. Gilmer's appointment to the Nominating and Corporate Governance Committee.
- Dr. Gilmer will be compensated for his services on the Nominating and Corporate Governance Committee pursuant to the compensation program for non-employee directors described in the Company's proxy statement dated April 27, 2026 for the Company's 2026 annual meeting of shareholders, except that his cash retainer for his service as a member of the Nominating and Corporate Governance Committee will be $5,000, in accordance with the changes implemented by the Board to the compensation program for non-employee directors for 2026.
Appointed: Daniel Gilmer, Director, effective 2026-04-24
On April 27, 2026, Armata Pharmaceuticals, Inc. (the "Company") announced that the Board of Directors (the "Board") appointed Dr. Daniel Gilmer, 39, as a member of the Board, effective as of April 24, 2026, to serve until the Company's next annual meeting of the Company's shareholders.
- The committee assignments of Dr. Gilmer have not been determined as of the time of this filing.
- Dr. Gilmer will participate in the Company's standard non-management director compensation arrangement.
- The Company pays non-management directors a retainer of $40,000 per year, payable in cash.
- Dr. Gilmer will also be eligible to receive equity awards in amounts to be determined by the Board pursuant to the Company's 2016 Stock Incentive Plan, as amended (the "Plan").
- In connection with his appointment, Dr. Gilmer is expected to receive an option award to purchase 51,280 shares of the Company's common stock, at an exercise price equal to the fair market value of one share of the Company's common stock on the date of grant, vesting in equal installments over a three-year period.
- The awards will be governed by the form of Stock Option Grant Notice and Option Agreement previously filed with the SEC on the Company's Quarterly Report on Form 10-Q filed on August 14, 2019.
Tools for this story
Each opens in a new tab, filled in for Armata Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.